Professor Colin Baigent
- Mexico City Prospective Study
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- SHARP: Study of Heart and Renal Protection
- ATT: Antithrombotic Trialists' Collaboration
- Coxib and traditional NSAID (CNT) Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- STT: Stroke Thrombolysis Trialists' Collaboration
- MTT: Marfan Treatment Trialists' Collaboration
- Trials Methodology
- Research Regulation
- UK HARP III
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Parish S. et al, (2018), Circ Genom Precis Med, 11
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.
Storey BC. et al, (2018), Kidney Int
The Role of Lipoprotein(a) in Chronic Kidney Disease.
Hopewell JC. et al, (2018), Journal of lipid research
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.
Patrono C. et al, (2017), J Am Coll Cardiol, 70, 1760 - 1776
ELECTIVE CONVERSION TO SIROLIMUS VS. CONTINUED TACROLIMUS IN KIDNEY TRANSPLANTATION (THE 3C STUDY): RESULTS OF A RANDOMIZED TRIAL
Haynes R. et al, (2017), TRANSPLANT INTERNATIONAL, 30, 63 - 64